Adding the SGLT2 inhibitor empagliflozin to standard treatment significantly improves left ventricular remodeling among patients with heart failure and reduced ejection fraction but without diabetes, shows a randomized controlled trial.
A systematic review and meta-analysis highlights a potential increase in the likelihood of achieving type 2 diabetes remission on a low- or very-low-carbohydrate diet, but based on evidence of moderate or low quality.
SGLT2 inhibitors are associated with lower rates of heart failure hospitalization, all-cause mortality, and hypoglycemia, but higher rates of diabetic ketoacidosis, when compared with DPP-4 inhibitors in older adults with type 2 diabetes, suggests a Canadian study.
Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.
Increased BMI and insulin resistance are important predictors of diabetic ketoacidosis risk among people with type 1 diabetes using SGLT2 inhibitors, say the authors of a meta-analysis and meta-regression.
A large number of people diagnosed with type 2 diabetes achieve intermediate or even normal glucose levels within the following few years, with regression to the mean accounting for more than half of these remissions, research suggests.
Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.